Investigational Bedtime Drug Modestly Reduces Sleep Apnea
The treatment reduced OSA severity by up to 45% and improved next-day blood pressure in people who also demonstrated a physiological response in upper airway collapsibility.
The treatment reduced OSA severity by up to 45% and improved next-day blood pressure in people who also demonstrated a physiological response in upper airway collapsibility.
Nyxoah SA announced the upcoming release of efficacy and safety data from the DREAM US pivotal study on the Genio neurostimulation system for obstructive sleep apnea.
The Luna TravelPAP is a small, lightweight positive airway pressure device with CPAP and AutoCPAP modes.
Digital solutions—from AI-powered mask fittings to telehealth CPAP adherence services—reshape how four durable medical equipment companies deliver care.
The investment will help prepare the device for volume manufacturing, develop the clinician and patient-led online platform, and achieve first sales.
Leveraging expertise across the health and wellness industry and with a track record in scaling companies, the new CEO will guide the company through its next phase of growth.
Avadel Pharmaceuticals' CEO says the "meaningful increase" in patients initiating therapy underscores the unmet need for a once-at-bedtime therapy.
While tonsil surgery is the primary treatment for OSA in children, medical literature and affected families have raised concerns about post-surgery weight gain and risk for obesity.
Allegheny Health Network has launched a new, evidence-based cognitive behavioral therapy for insomnia program to help patients with insomnia improve their sleep quality and quantity.